Open this publication in new window or tab >>Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands.
Institute of Immunology, University Medical Center Mainz, Langenbeckstr.1, Mainz, Germany.
Glycosciences Laboratory, Imperial College London, London, United Kingdom.
Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10−14, Mainz, Germany.
AFFINImeter Scientific & Development Team, Software 4 Science Developments, A Coruña, Santiago de Compostela, Spain; Departamento de Física Aplicada, Facultad de Física, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Division of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, MA, Boston, United States.
Institute of Immunology, University Medical Center Mainz, Langenbeckstr.1, Mainz, Germany.
Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands.
Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10−14, Mainz, Germany.
Umeå University, Faculty of Science and Technology, Department of Chemistry.
School of Biological and Chemical Sciences, University of Galway, University Rd., Galway, Ireland; SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, University of Galway, University Rd., Galway, Ireland.
Show others...
2023 (English)In: Journal of the American Chemical Society, ISSN 0002-7863, E-ISSN 1520-5126, Vol. 145, no 24, p. 13027-13037Article in journal (Refereed) Published
Abstract [en]
Mucin expression and glycosylation patterns on cancer cells differ markedly from healthy cells. Mucin 1 (MUC1) is overexpressed in several solid tumors and presents high levels of aberrant, truncated O-glycans (e.g., Tn antigen). Dendritic cells (DCs) express lectins that bind to these tumor-associated carbohydrate antigens (TACAs) to modulate immune responses. Selectively targeting these receptors with synthetic TACAs is a promising strategy to develop anticancer vaccines and to overcome TACA tolerance. In this work, we prepared, via a solid phase peptide synthesis approach, a modular tripartite vaccine candidate, incorporating a high-affinity glycocluster based on a tetraphenylethylene scaffold, to target the macrophage galactose-type lectin (MGL) on antigen presenting cells. MGL is a C-type lectin receptor that binds Tn antigens and can route them to human leukocyte antigen class II or I, making it an attractive target for anticancer vaccines. Conjugation of the glycocluster to a library of MUC1 glycopeptides bearing the Tn antigen is shown to promote uptake and recognition of the TACA by DCs via MGL. In vivo testing revealed that immunization with the newly designed vaccine construct bearing the GalNAc glycocluster induced a higher titer of anti-Tn-MUC1 antibodies compared to the TACAs alone. Additionally, the antibodies obtained bind a library of tumor-associated saccharide structures on MUC1 and MUC1-positive breast cancer cells. Conjugation of a high-affinity ligand for MGL to tumor-associated MUC1 glycopeptide antigens has a synergistic impact on antibody production.
Place, publisher, year, edition, pages
American Chemical Society (ACS), 2023
National Category
Other Basic Medicine
Identifiers
urn:nbn:se:umu:diva-211840 (URN)10.1021/jacs.2c12843 (DOI)001008122000001 ()37279388 (PubMedID)2-s2.0-85162847018 (Scopus ID)
Funder
German Research Foundation (DFG), CRC 1066EU, Horizon 2020, ERC CoG SUPRAVACC819856The Kempe Foundations, JCK-1819.1The Kempe Foundations, JCK-1819.2
2023-07-112023-07-112023-07-11Bibliographically approved